Pulmocide Raises $92 million in a Series C Financing to Fund Registration Program for PC945

NEXT STORY
Oncorus Announces Nomination of its First IV-Administered Synthetic Viral RNA (vRNA) Immunotherapy Product Candidates, ONCR-021 and ONCR-788
PREV STORY
Middle East & Africa Microplate Reader Market Forecast to 2027 – COVID-19 Impact and Regional Analysis By Type, Application, and End User
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Immune Design Reports Data Update for Lead Immunotherapy Programs: Improvement in Survival for CMB305 Monotherapy in Sarcoma and Increased Objective Responses for G100/pembrolizumab Combination in Follicular Lymphoma

Median overall survival of 23.7 months following CMB305 monotherapy represents approximately one-year extension of ...

author_avatar
NASDAQ Market News

Apricus Biosciences Files NDA Resubmission for Vitaros™

SAN DIEGO, Aug. 29, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical ...

author_avatar
NASDAQ Market News

Liverpool Heart and Chest Hospital NHS Foundation Trust extends partnership with Allscripts

LIVERPOOL, United Kingdom, Sept. 28, 2017 (GLOBE NEWSWIRE) -- Liverpool Heart and Chest Hospital ...

author_avatar
NASDAQ Market News